Brian Mehling, M.D., a board-certified orthopedic surgeon and CMO of Blue Horizon International, presented his study on intravenously administered human cord blood stem cells in the treatment of symptoms related to chronic inflammation.
NEW YORK, March 14, 2016 /PRNewswire/ — Internationally recognized stem cell researcher and chief medical officer of Blue Horizon International (BHI) and BHI Therapeutic Sciences, Brian Mehling, M.D. presented at the World Congress on Cell & Stem Cell Research in Philadelphia, USA.
The World Congress on Cell & Stem Cell Research was held February 29 – March 2, 2016. Researchers, medical practitioners, and company representatives from around the world came together at the Congress Center to present and discuss the latest developments and findings in the fields of stem cell research, cell therapy, biomaterials, and tissue engineering.
The event has evolved into an outstanding platform for international networking and for showcasing joint scientific work in the field of regenerative medicine.
“Stem cell therapies are, without a doubt, the future of medicine and we believe their role in treatments will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” Dr. Mehling stated. “It is important that doctors and medical professionals are educated on what direction the world will take in regard to stem cell research and therapies. The possibilities are endless. It is crucial for physicians to be aware of the therapies available for patients with different chronic conditions, disorders, and acute diseases.”
BHI Therapeutic Sciences, LLC is currently offering cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and is fully licensed by the Ministry of Health of the Slovak Republic.
Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research and philanthropic efforts. Across the globe quality care and services for medical treatments are provided along with resources needed to assist children and adults who are medically underserved. For more information, please visit Blue Horizon International at www.bluehorizoninternational.com
OMICS International and its subsidiaries including iMedPub LLC and Conference Series LLC Organise 3000+ Conferences across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
OMICS International is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology “Open Access”, OMICS International publishes 700 online open access scholarly journals in all aspects of Science, Engineering, Management and Technology journals. OMICS International has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS International also organizes 3000 International conferences across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.